好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Shared Decision Making in the NeuroICU ‘Goes Digital’: Preliminary Acceptability and Usability Testing of a Digital Web-Based Decision Aid for Goals-of-Care Decisions in Critically Ill Severe Acute Stroke Patients
Neuro Trauma, Critical Care, and Sports Neurology
Neurocritical Care Posters (7:00 AM-5:00 PM)
048

To field-test a preliminary digital decision aid (DA) for critically ill severe acute stroke (SAS) patients to understand acceptability and usability, and obtain feedback from surrogate decision-makers.

 

Shared decision making (SDM) has been recommended for important decisions in ICUs by many professional societies and the Institute of Medicine. We have recently developed a paper-based SDM tool (decision aid [DA]) for surrogates of severe acute ischemic and hemorrhagic stroke (SAS) patients facing the life-or-death goals-of-care decision using stakeholder input. Then we converted this DA to a digital, web-based tool to increase accessibility and portability to allow surrogates, who are often geographically separated, to partake in SDM. We sought to obtain feedback from surrogates on this tool and understand its acceptability and usability.

We recruited family members of neuroICU patients from the waiting room at a single center (UMass). As they read through the DA, we monitored for usage time, navigational difficulties and points of confusion. We then documented subjects’ verbal feedback and applied validated scales for usability (System Usability Scale [SUS]) and acceptability.

We recruited 9 surrogates over a period of 3 weeks. Median total usage time was 26 minutes (25-31). Several participants had minor navigational issues during use but adjusted quickly. Median SUS was 90 (where SUS >68/100 is considered “good usability”). On the acceptability scale, 91% of participants graded the DA as good or excellent, with all subcategories scored favorably between 78-100%. Notable surrogate feedback included a particular appreciation for the worksheet and criticism of the DA as text-heavy.

Our pilot digital DA achieved high usability and acceptability. However, the current DA needs a reduction in text and an improved user interface to optimize the user experience. We are currently applying for funding to refine our digital DA and perform feasibility testing.

Authors/Disclosures
Abigail S. Bose, MD (UMass Medical Center)
PRESENTER
Dr. Bose has nothing to disclose.
Uzair A. Khalid, MBBS Dr. Khalid has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Susanne Muehlschlegel, MD, MPH, FAAN (Johns Hopkins School of Medicine) Dr. Muehlschlegel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acasti Pharma Inc.. Dr. Muehlschlegel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acasti Pharma Inc.. The institution of Dr. Muehlschlegel has received research support from NIH. The institution of Dr. Muehlschlegel has received research support from NIH. The institution of an immediate family member of Dr. Muehlschlegel has received research support from NIH. The institution of Dr. Muehlschlegel has received research support from Johns Hopkins Stimulating and Advancing Anesthesiology & Critical Care Medicine Research (StAAR) Award. The institution of Dr. Muehlschlegel has received research support from Trustees of The Patrick and Catherine Weldon Donaghue Medical Research Foundation. The institution of Dr. Muehlschlegel has received research support from Harkin Family Fund (Johns Hopkins Dept. of Neurology). Dr. Muehlschlegel has received personal compensation in the range of $500-$4,999 for serving as a Speaker and Author with 好色先生. Dr. Muehlschlegel has a non-compensated relationship as a Member of Board of Directors with Neurocritical Care Society that is relevant to AAN interests or activities.